Telehealth provider Teladoc last week accused Amwell of infringing on its patents and demanded that its rival stop offering the products in question — setting the stage for a potential legal dispute between the two most prominent companies in telemedicine.

In a Sept. 14 letter to Amwell obtained by STAT, Teladoc’s intellectual property attorneys pointed to Amwell’s digital scope and stethoscope, as well as several of its telemedicine carts — wheeled devices equipped with cameras and screens that telehealth providers use to connect remote clinicians with patients on-site. The letter, addressed to Amwell’s CEOs, Ido and Roy Schoenberg, alleges that one or more of these products “directly and indirectly infringe” patents that Teladoc took ownership of earlier this year through an acquisition of telemedicine startup InTouch in a deal announced in January.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy